Background
==========

Obstructive sleep apnea (OSA), is the most prevalent form of sleep disordered breathing both in adults and children \[[@B1]-[@B3]\] and has been associated with significant neurocognitive, metabolic, and cardiovascular morbidities \[[@B4]-[@B8]\]. OSA is characterized by episodes of total and/or partial collapse of the upper airway alternating with normal breathing during sleep, leading to chronic intermittent hypoxia and hypercapnia, sleep fragmentation and increased swings in intrathoracic pressures. This condition may affect 1-- 3% of healthy school-aged children \[[@B2]\]. There is accumulating evidence that OSA is strongly linked to cardiovascular morbidity independent of obesity \[[@B9]-[@B11]\]. The presence of altered endothelial function is currently viewed as an early risk marker of cardiovascular disease, and is a relatively common occurrence in both adult and pediatric patients with OSA \[[@B12]-[@B14]\], and can precede the onset of hypertension \[[@B15]\]. However, not every child with OSA will develop ED, suggesting that genetic factors may play a role.

Nitric oxide synthase (*NOS*) is encoded by three distinct genes, namely neuronal NOS (*nNOS, NOS1*), inducible NOS (*iNOS, NOS2*), and endothelial NOS (*eNOS, NOS3*), which are located on chromosomes 12, 17 and 7, respectively. Studies have examined the possibility that SNPs in these genes may influence their expression and functional activity, and potentially alter the predisposition to cardiovascular disease \[[@B16]-[@B18]\]. Accordingly, single nucleotide polymorphisms (SNPs) have been identified in NOS genes, and their association with coronary artery disease, hypertension, and diabetes has been explored \[[@B19]-[@B22]\]. Considering the potential role of these enzymes in either OSA or its downstream adverse consequences, it is somewhat surprising that the potential associations between NOS polymorphisms and OSA remain thus far unexplored.

The endothelins (*EDN*) are a family of endothelium-derived peptides that possess vasoconstrictor properties, and are important mediators of both physiological and pathophysiologic processes \[[@B23]\]. The genes encoding for *EDN-1,-2* and*-3* are located on chromosomes 6, 1, and 20, respectively \[[@B24]\]. Several studies have been identified various SNPs on *EDN* genes and also in the genes encoding for their cognate receptors (*EDNRA* and *EDNRB*), and some of these gene variants have been associated with altered susceptibility and prognosis of diseases such as heart failure, dilated cardiomyopathy, diabetic retinopathy, and atherosclerosis \[[@B25]-[@B31]\]. Furthermore, genetic polymorphisms in the endothelin-receptor-subtype-A (*EDNRA*) gene have been identified as conferring increased susceptibility for OSA in adults \[[@B32]\].

Based on aforementioned considerations, we hypothesized that single nucleotide polymorphisms (SNPs) in *NOS-* and *EDN*-related genes in children may contribute to the risk of pediatric OSA or its downstream vascular consequences.

Methods
=======

Subjects
--------

The study was approved by the University of Louisville Human Research Committee, and informed consent was obtained from the legal caretaker of each participant. Consecutive healthy pre-pubertal children (ages 5--10 years) were recruited from the community, and the cohort was enriched for the presence of habitual snoring. All children underwent a standard polysomnographic evaluation in the sleep laboratory at the University of Louisville Pediatric Sleep Laboratory, after which assessment of endothelial function (when possible) and a blood draw were performed between 7:00 to 8:00AM in fasting conditions.

Overnight polysomnography
-------------------------

A standard overnight multichannel polysomnographic evaluation was performed in the sleep laboratory as described previously \[[@B33]\]. Sleep architecture was assessed by standard techniques \[[@B34]\]. The proportion of time spent in each sleep stage was expressed as percentage of total sleep time (%TST). Obstructive apnea was defined as the absence of airflow with continued chest wall and abdominal movement for duration of at least two breaths \[[@B33]\]. Hypopneas were defined as a decrease in oronasal flow of ≥50% with a corresponding decrease in SpO~2~ of ≥4% and/or arousal \[[@B33]\]. The obstructive apnea/hypopnea index was defined as the number of apneas and hypopneas per hour of TST. Arousals were defined as recommended \[[@B35]\] and included respiratory-related (occurring immediately following an apnea, hypopnea, or snore), technician-induced, and spontaneous arousals. Arousals were expressed as the total number of arousals per hour of sleep time (arousal index). Control children required the presence of an AHI\<2 in the absence of a history of snoring as well as no snoring detected during the sleep study. Habitually snoring children with AHI\>2/hrTST and a nadir oxyhemoglobin saturation \<92% were considered to have OSA \[[@B33]\].

Body mass index
---------------

Children were weighed using the InBody 320 scale (Biospace; Cerritos, CA), and height (to 0.1 cm) was measured using a stadiometer (Holtain, Crosswell, UK). The BMI was calculated and the BMI *z*-score was computed using US Centers for Disease Control and Prevention 2000 growth standards (<http://www.cdc.gov/growthcharts/>) and online software (<http://wwwn.cdc.gov/epiinfo/>). A BMI *z*-score \> 1.65 (\> 95th percentile) was considered as fulfilling obesity criteria.

Sphygmomanometry
----------------

All children had arterial blood pressure measured noninvasively using an automated mercury sphygmomanometer (Welch Allyn; Skaneateles Falls, New York) at the brachial artery, using the appropriate cuff size on the non-dominant arm.\[[@B36]\] Systolic BP and diastolic BP indices were calculated by dividing the average systolic and diastolic pressure by the respective 95th percentile for BP using National Heart, Lung and Blood Institute guidelines <http://www.nhlbi.nih.gov/guidelines/hypertension/child_tbl.htm>), computed for age, sex, and height. Hypertension was defined when the SBPi or DBPi was \> 1.

Endothelial function tests
--------------------------

Endothelial function was assessed upon awakening from the sleep study in the morning, using a modified hyperemic test after cuff-induced occlusion of the radial and ulnar arteries as previously described \[[@B14],[@B15],[@B37],[@B38]\]. Briefly, a laser Doppler sensor (Periflux 5000 System, Perimed, Jarfalla, Sweden) was applied over the volar aspect of the hand at the 1st finger distal metacarpal surface and the hand was gently immobilized. Once cutaneous blood flow over the area became stable, the pressure within an inflatable cuff placed at the forearm and connected to a computer-controlled manometer was raised to 200 mmHg for 60 sec during which blood flow was reduced to undetectable levels. The cuff was rapidly deflated and the laser Doppler measured hyperemic responses. As previously shown, the time to peak regional blood flow after occlusion release (Tmax) is highly reproducible and is representative of the post-occlusion hyperemic response, an index of endothelial function \[[@B39]\]. A Tmax value ≥45 sec was considered as the criterion for abnormal endothelial function as previously described \[[@B9],[@B10],[@B14],[@B15],[@B37],[@B38]\].

DNA extraction
--------------

Peripheral blood samples were collected in vacutainer tubes containing EDTA (Becton Dickinson, Franklin Lakes, NJ, USA). All DNA samples were extracted using QIAmp DNA blood kit (Qiagen, Valencia, CA) according the manufacturer's protocol. The concentration and quality of the DNA were determined using a ND-1000 Spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA). The precise length of genomic DNA was determined by gel electrophoresis using 1% agarose gel. All the purified samples were stored at −80°C until further analyses.

Custom cardiovascular gene SNP array
------------------------------------

The IBC array was developed using SNP and linkage disequilibrium information from the HapMap as well as data from Seattle SNPs, and National Institute of Environmental Health Sciences (NIEHS) SNPs \[[@B40]\]. Briefly, the IBC array contains about 50,000 SNPs from genetic diversity across approximately 2100 genes related to cardiovascular, inflammatory, hemostasis/coagulation, and metabolic phenotypes and pathways. Among those genes, we selected the NOS genes which include *NOS1* (209 SNPs), *NOS2* (122 SNPs) and *NOS3* (50 SNPs). Furthermore, we selected the EDN and EDN receptor genes family which includes EDN1 (43 SNPs), *EDN2* (48 SNPs), *EDN3* (14SNPs), *EDNRA* (27 SNPs) and *EDNRB* (23 SNPs). SNPs were clustered into genotypes with the Illumina Beadstudio software and subjected to quality-control filters at the sample and SNP levels separately within each cohort. Samples were excluded for individual call rates \<90%, gender mismatch, and duplicate discordance. SNPs were removed for call rates \<95% or Hardy-Weinberg Equilibrium p \<10^−7^ in controls from each cohort (regardless of ethnicity). Due to the low-frequency SNPs included in the design and the aim to capture low-frequency variants of large effect across the large dataset, we filtered only on minor allele frequency (MAF) \< 0.005.

Total RNA isolation
-------------------

Fasting peripheral blood samples were drawn from children within the first hour after awakening and collected in PAXgene Blood RNA tubes (Becton Dickinson, UK). Total RNA was isolated using PAXgene Blood RNA Kit and treated with DNase I (QIAGEN, CA), according to the manufacturer's protocol. The RNA quantity and integrity were determined using a Nanodrop Spectrophotometer and Agilent 2100 Bioanalyzer Nano 6000 LabChip assay (Agilent Technologies, Santa Clara, CA).

qPCR validation
---------------

Quantitative real-time PCR (QRT-PCR) were performed using the ABI 7500 instrument (Applied Biosystems, Foster City, CA). Complementary DNA was synthesized using a High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, CA). Five hundred nanograms (500 ng) of total RNA from NOSA and OSA samples were used to generate cDNA templates for RT-PCR with primer specific for EDN1 gene. The TaqMan® Master Mix Reagent Kit (Applied Biosystems, Foster City, CA) was in 25 μl reactions. Various negative controls were included in the PCR reaction to ensure specific amplification. Triplicate PCR reactions were performed in 96-well plates for each gene in parallel with the 18S rRNA. The steps involved in the reaction program included: the initial step of 2 minutes at 50°C; denaturation at 95°C for 10 min, followed by 45 thermal cycles of denaturation (15 seconds at 95°C) and elongation (1 min at 60°C). The expression values were obtained from the cycle number (*Ct* value) using the Biosystems analysis software. The threshold cycle (*C*~T~) values were averaged from each reaction, and each gene was normalized to the 18S rRNA level. These Ct values were averaged and the difference between the 18S Ct (Avg) and the gene of interest Ct (Avg) was calculated (Ct-diff). The relative expression of the gene of interest was analyzed using the 2^-ΔΔCT^ method \[[@B41]\]. Quantitative results are expressed as the mean ±standard deviation (SD). Statistical significance was evaluated by the Student's *t*-test.

Statistical analysis
--------------------

All analyses were conducted using SPSS software (version 19.0; SPPS Inc., Chicago, Ill.), and data are presented as mean ± SD. The association analysis was assessed by using Pearson's chi-square test implemented in SPSS. A P-value \< 0.05 was considered statistically significant for all analyses. Odd ratio and 95% confidence interval were calculated for the minor allele of each SNP. The Haploview version 4.2 software (<http://hppt://www.borad.mit.edu/mpg/haploview>) was used to analyze the linkage disequilibrium structure, calculating D' to define haplotype block \[[@B42]\] and to estimate haplotype frequencies. Additionally, pair-wise linkage disequilibrium (LD) among the SNPs was examined using Lewontin's standardized coefficient D' and LD coefficient r2 \[[@B43]\], and haplotype blocks were defined according to the method of Gabriel et al. \[[@B42]\] in Haploview 4.2 with default settings. Haplotypes within these blocks were estimated using the estimation of maximization algorithm \[[@B44]\]. The associations derived from the comparisons across OSA and NOSA were assessed in terms of odds ratios (OR) both unadjusted and adjusted for age, gender, ethnicity, and obesity with the corresponding 95% confidence interval (CI).

Results
=======

The recruitment process of children in this study is shown in Figure [1](#F1){ref-type="fig"}. As indicated in Figure [1](#F1){ref-type="fig"}, 970 subjects were recruited, and 362 were excluded from the study because they had chronic medical conditions, such as known genetic syndromes, severe asthma or allergies, or they were receiving chronic medications. A total of 608 children were therefore included, and divided into two groups based on their apnea-hypopnea index (AHI) results in the sleep study: 480 children were controls (NOSA) and 128 children fulfilled the criteria for OSA (OSA) based on AHI. The demographic characteristics and polysomnographic findings of children with OSA and NOSA groups are shown in Table [1](#T1){ref-type="table"}, and show markedly similar age, gender, and ethnic distribution indicating that the 2 groups were overall matched for these characteristics. As would be expected based on category attribution criteria, the AHI, apnea index and arousal index were all significantly higher in the OSA group (P\<0.0001). Furthermore, mean SpO2 levels in OSA were significantly lower than NOSA group (P\<0.001). Notably, we did not find any significant differences in systemic blood pressure among the 2 groups.

![**Schema illustrating the recruitment process in this study.** Children were matched for age, gender and ethnicity. Children were excluded from the study, if they had any chronic medical conditions such as known genetic syndromes, severe asthma or allergies, or if they were on any chronic medications.](1755-8794-6-29-1){#F1}

###### 

Demographic characteristics in children with and without OSA

  **Variables**             **NOSA**       **OSA**        ***P-value***
  ------------------------- -------------- -------------- ---------------
  Age (years)               7.14±1.00      7.04±0.99      0.14
  Gender (% male)           58.9           55.5            
  Ethnicity                                                
  White Caucasian %         72             63.3            
  African American %        28             36.7            
  BMI z-score               0.81±1.24      1.23±1.38      0.002
  SBP (mmHg)                105.46±10.98   105.86±8.05    0.44
  DBP (mmHg)                61.80±7.65     63.96±5.53     0.11
  Sleep latency (min)       23.76±23.99    19.45±20.71    0.02
  REM latency (min)         151.88±62.77   155.24±80.95   0.33
  TST (min)                 468.77±44.90   469.28±55.29   0.46
  Sleep efficiency (%)      88.79±7.89     89.35±9.80     0.28
  Stage 1 (% TST)           6.08±4.61      6.05±5.85      0.48
  Stage 2 (% TST)           46.32±12.73    43.62±7.93     0.002
  Slow wave sleep (% TST)   27.67±9.43     28.91±8.08     0.07
  REM sleep (%TST)          20.68±8.35     20.13±10.87    0.30
  AHI (h-1 TST)             0.63±0.49      8.28±9.27      \<0.0001
  Apnea index (h-1 TST)     0.44±0.96      2.53±4.76      \<0.0001
  Arousal index (h-1 TST)   10.06±7.25     13.37±7.82     \<0.0001
  Mean SaO2 (%)             97.21±4.82     96.24±2.23     0.0006
  Lowest SaO2 (%)           92.66±3.85     86.02±9.10     \<0.0001

From a total of 381 SNPs assayed for the 3 *NOS-1*,-*2* and*-3* genes, 15 SNPs in the *NOS1* gene and 1 SNP for *NOS3* gene exhibited statistically significant differences in their frequencies among children with OSA and their matched controls, even after correction for multiple comparisons (Table [2](#T2){ref-type="table"}). Linkage disequilibrium (LD) analysis of the 15 SNPs in the *NOS1* gene was assessed for both OSA and NOSA subjects. In NOSA subjects, two haplotype blocks emerged, and are outlined in black triangular regions in Figure [2](#F2){ref-type="fig"} (Panel A). In OSA subjects, the haplotype showed the presence of 2 blocks as well (Figure [2](#F2){ref-type="fig"}, Panel B). The haplotype of these blocks and their frequencies in OSA and NOSA are shown in Figure [3](#F3){ref-type="fig"}, Panels A and B, respectively. Taken together, the patterns of LD and haplotype frequencies differed between OSA and NOSA, suggesting that some of these SNPs may contribute to OSA risk.

###### 

Distributions of allele and genotype frequencies of NOS SNPs in children with and without OSA

  **Gene**   **SNP**      **Allele**   **NOSA**   **OSA**   **P-value**   **OR**   **CI 95%**       
  ---------- ------------ ------------ ---------- --------- ------------- -------- ------------ --- ---
  NOS1       rs9658535    A/G          n=477      n=128     0.04          0.26     0.07--1.06       
  n          \%           n            \%                                                           
  AA         421          88           116        91                                                
  GA         52           11           8          6                                                 
  GG         4            1            4          3                                                 
  Allele A   894          94           240        94                                                
  Allele G   60           6            16         6                                                 
             rs7960451    C/T          n=480      n=128     0.02          0.21     0.05--0.78       
  n          \%           n            \%                                                           
  CC         417          87           112        87                                                
  TC         59           12           11         9                                                 
  TT         4            1            5          4                                                 
  Allele C   893          93           235        92                                                
  Allele T   67           7            21         8                                                 
             rs4767524    C/G          n=478      n=128     0.04          0.71     0.43--1.15       
  n          \%           n            \%                                                           
  CC         160          33           52         41                                                
  GC         242          51           49         38                                                
  GG         76           16           27         21                                                
  Allele C   562          59           153        60                                                
  Allele G   394          41           103        40                                                
             rs2293050    A/G          n=478      n=128     0.0002        1.59     1.04--2.43       
  n          \%           n            \%                                                           
  AA         82           17           13         10                                                
  AG         208          44           78         61                                                
  GG         188          39           37         29                                                
  Allele A   372          39           104        41                                                
  Allele G   584          61           152        59                                                
             rs10744891   G/T          n=465      n=121     0.004         1.72     0.90--3.28       
  n          \%           n            \%                                                           
  GG         185          40           35         29                                                
  TG         206          44           74         61                                                
  TT         74           16           12         10                                                
  Allele G   576          62           144        60                                                
  Allele T   354          38           98         40                                                
             rs9658354    A/T          n=478      n=126     0.001         1.74     1.13--2.68       
  n          \%           n            \%                                                           
  AA         80           17           13         10                                                
  AT         211          44           79         63                                                
  TT         187          39           34         27                                                
  Allele A   371          39           105        42                                                
  Allele T   585          61           147        58                                                
             rs2139733    A/T          n=478      n=128     0.002         1.65     1.08--2.52       
  n          \%           n            \%                                                           
  AA         77           16           13         10                                                
  AT         209          44           78         61                                                
  TT         192          40           37         29                                                
  Allele A   363          38           104        41                                                
  Allele T   593          62           152        59                                                
             rs1520810    A/T          n=478      n=127     0.03          0.86     0.38--1.94       
  n          \%           n            \%                                                           
  AA         263          55           85         67                                                
  TA         189          40           34         27                                                
  TT         26           5            8          6                                                 
  Allele A   715          75           204        80                                                
  Allele T   241          25           50         20                                                
             rs471871     A/T          n=478      n=127     0.01          0.55     0.37--0.82       
  n          \%           n            \%                                                           
  AA         51           11           13         10                                                
  AT         212          44           38         30                                                
  TT         215          45           76         60                                                
  Allele A   314          33           64         25                                                
  Allele T   642          67           190        75                                                
             rs528558     A/G          n=479      n=128     0.03          0.61     0.41--0.92       
  n          \%           n            \%                                                           
  AA         26           5            8          6                                                 
  AG         191          40           35         27                                                
  GG         262          55           85         66                                                
  Allele A   243          25           51         20                                                
  Allele G   715          75           205        80                                                
             rs816296     A/C          n=478      n=127     0.04          0.58     0.38--0.89       
  n          \%           n            \%                                                           
  AA         24           5            4          3                                                 
  AC         174          36           33         26                                                
  CC         280          59           90         71                                                
  Allele A   222          23           41         16                                                
  Allele C   734          77           213        84                                                
             rs579604     C/T          n=479      n=128     0.04          N/A      N/A              
  n          \%           n            \%                                                           
  CC         310          65           96         75                                                
  TC         158          33           32         25                                                
  TT         11           2            0          0                                                 
  Allele C   778          81           224        88                                                
  Allele T   180          19           32         12                                                
             rs1552227    C/T          n=479      n=128     0.02          0.47     0.22--0.97       
  n          \%           n            \%                                                           
  CC         294          61           63         49                                                
  TC         163          34           53         42                                                
  TT         22           5            12         9                                                 
  Allele C   751          78           179        70                                                
  Allele T   207          22           77         30                                                
             rs17509231   C/T          n=478      n=128     0.02          0.40     0.07--2.41       
  n          \%           n            \%                                                           
  CC         395          83           92         72                                                
  TC         80           17           34         26                                                
  TT         3            0            2          2                                                 
  Allele C   870          91           218        85                                                
  Allele T   86           9            38         15                                                
             rs3782221    A/G          n=477      n=128     0.02          0.61     0.41--0.90       
  n          \%           n            \%                                                           
  AA         36           7            4          3                                                 
  AG         213          45           47         37                                                
  GG         228          48           77         60                                                
  Allele A   285          30           55         21                                                
  Allele G   669          70           201        79                                                
  NOS3       rs1800780    A/G          n=470      n=126     0.05          0.71     0.47--1.09       
  n          \%           n            \%                                                           
  AA         103          22           16         13                                                
  AG         240          51           67         53                                                
  GG         127          27           43         34                                                
  Allele A   446          47           99         39                                                
                          Allele G     494        53        153           61                         

![**Pairwise linkage disequilibrium (LD) structure and 15 SNPs of the*NOS1*gene.** Panel **(A)** represents children without OSA (NOSA), and Panel **(B)** represents children with OSA (OSA). The plot was generated using Haploview 4.2 with D' Color Scheme (D'=0, D'\<1 and D'=1 shown by white, shades of pink and red (respectively) and pairwise r^2^ values shown in diamonds. The value within each diamond represents the pair-wise LD (correlation, measured as D') between the two SNPs defined by the top left and the top right of the diamond. Solid lines represent SNPs that were used in the haplotype analysis, and are part of the haplotype from SNP block whereas dashed lines represent SNPs that were used in the analysis, but were not part of the haplotype.](1755-8794-6-29-2){#F2}

![**Haplotype frequencies in children with and without OSA.** Panel **(A)** represents haplotype for children without OSA (NOSA), and Panel **(B)** represents haplotype for children with OSA (OSA).](1755-8794-6-29-3){#F3}

From a total of 155 SNPs for the three *EDN-1,-2* and*-3* genes and their associated *EDN* receptors (*EDNRA* and *EDNRB*), there were 4 SNPs in *EDN1*, and 1 SNP in both of *EDN2* and *EDN3*, in which allelic frequencies were significantly altered in children with OSA (Table [3](#T3){ref-type="table"}). No differences emerged for *EDN* receptor (*EDNRA*, *EDNRB*) SNPs. The list and the summary of the significant SNPs in both *NOS* and *EDN* genes such as location of these SNPs, percentage of minor allele frequency (%MAF) are shown in Additional file [1](#S1){ref-type="supplementary-material"}: Table S1.

###### 

Distributions of allele and genotype frequencies of EDN SNPs in children with and without OSA

  **Gene**    **SNP**      **Allele**   **NOSA**   **OSA**   **P-value**   **OR**      **CI 95%**       
  ----------- ------------ ------------ ---------- --------- ------------- ----------- ------------ --- ---
  EDN1        rs1014505                 n=478      n=127     \<0.001       1.28        0.85-1.92        
  C/G         n            \%           n          \%                                                   
  CC          62           13           36         29                                                   
  CG          215          45           45         35                                                   
  GG          201          42           46         36                                                   
  Allele C    339          35           117        46                                                   
  Allele G    617          65           137        54                                                   
  rs2070698   C/T          n=480        n=128      0.04      1.73          1.07-2.79                    
  n           \%           n            \%                                                              
  CC          102          21           37         29                                                   
  CT          236          49           66         52                                                   
  TT          142          30           25         19                                                   
  Allele C    440          46           140        55                                                   
  Allele T    520          54           116        45                                                   
  rs2248580                n=478        n=128      0.02      1.07          0.72-1.59                    
  A/C         n            \%           n          \%                                                   
  AA          60           12           28         22                                                   
  AC          208          44           46         36                                                   
  CC          210          44           54         42                                                   
  Allele A    328          34           102        40                                                   
  Allele C    628          66           154        60                                                   
  rs2070699   G/T          n=479        n=128      0.002     0.42          0.25-0.69                    
  n           \%           n            \%                                                              
  GG          213          45           55         43                                                   
  TG          216          45           45         35                                                   
  TT          50           10           28         22                                                   
  Allele G    642          67           155        61                                                   
  Allele T    316          33           101        39                                                   
  EDN2        rs11210273   C/T          n=478      n=128     0.02          NA          NA               
  n           \%           n            \%                                                              
  CC          411          86           105        82                                                   
  TC          67           14           21         16                                                   
  TT          0            0            2          2                                                    
  Allele C    889          93           231        90                                                   
  Allele T    67           7            25         10                                                   
  EDN3        rs6064764    C/T          n=479      n=127     0.02          0.90        0.60-1.34        
  n           \%           n            \%                                                              
  CC          27           6            15         12                                                   
  CT          174          36           35         27                                                   
  TT          278          58           77         61                                                   
  Allele C    228          24           65         26                                                   
                           Allele T     730        76        189           74                            

Next, we divided OSA subjects into 2 subgroups based on their individual Tmax values, when such values were available: OSA with normal endothelial function (OSA-NEF), and OSA with endothelial dysfunction (OSA-ED). As shown in Figure [4](#F4){ref-type="fig"}, Tmax values were significantly higher in the 6 OSA-ED subjects compared to 17 subjects with OSA-NEF (P\<0.002).

![Individual Tmax values in children with OSA and normal endothelial function (OSA-NEF), and children with OSA with endothelial dysfunction (OSA-ED).](1755-8794-6-29-4){#F4}

In addition, we quantified the mRNA expression of the *EDN1* gene in 18 matched subjects, 9 with NOSA and 9 with OSA using qRT-PCR. As shown in Figure [5](#F5){ref-type="fig"}, *EDN1* was significantly increased in children with OSA compared to NOSA (*P*-value 0.0005).

![**qRT-PCR analysis for*EDN1*gene expression in children with OSA and controls (NOSA).** Data are presented as relative mRNA expression levels normalized to 18s, and individual values and boxplots are shown (OSA vs. NOSA: *P*-value \<0.0005).](1755-8794-6-29-5){#F5}

Discussion
==========

In this study, we report on the allelic frequencies associations of *NOS* and *EDN* gene families in children with and without OSA. The frequency of specific NOS1 and EDN1 SNPs was significantly associated with the presence of OSA, while the frequencies of all other SNPs tested for the *NOS* and *EDN* genes did not show any significant differences between OSA and NOSA. In addition, a subset of the children with OSA showed evidence of endothelial dysfunction even though they were asymptomatic and identified through community-based systematic surveys, thereby confirming previous findings in clinical cohorts on the adverse effect of OSA on endothelial function. Furthermore, in a small subset of children for whom RNA samples were available from peripheral blood monocytes, *EDN1* gene expression was elevated in children with OSA compared to controls.

Before we discuss the potential significance of our findings, some methodological issues deserve comment, in particular subject selection considerations and genetic variances. First, we excluded any child with known diabetes, hypertension, or any other chronic disease condition. This approach could therefore have artificially reduced the magnitude of the association of any given *NOS* of *EDN* allelic variant with OSA. Second, we narrowed the age range of the current cohort such as to minimize as much as possible any confounding factors that might be operational across a wide age range in OSA. Thirdly, closely matched control children are included which should minimize the effect of modifying factors that could be involved in the process of subject selection. In addition, the use of the laser Doppler technique for assessment of vascular responses following cuff-induced arterial occlusion not only permits reproducible determination of the kinetics of post-ischemic reperfusion, but also serves as an accurate reporter of nitric oxide-mediated physiological recruitment of the microvasculature \[[@B37],[@B45]\]. In this context, we also excluded children with a variety of diagnoses that can be associated with endothelial dysfunction \[[@B46]\]. The two important limitations of this study include the relatively small size of the cohort of children studied which could hamper statistical power, and the absence of endothelin plasma level measurements in blood cells for the genes of interest. Although highly desirable, the latter were not possible due to limitations in the amount of blood samples. However, inclusion of the present preliminary findings on endothelial function are intent on further illustrating future directions that will need to encompass specific gene variants to not only the presence or absence of a disorder, i.e., OSA, but also to the presence or absence of a consequence of the disorder, i.e., endothelial dysfunction. We and others have previously shown significant associations between specific gene candidate variances and OSA-associated phenotypes, and this study adds incremental information to potentially significant contributions of *EDN* and NOS gene polymorphisms to this issue \[[@B8],[@B47]-[@B51]\]. However, the overall modulatory effects of these polymorphisms to the clinical phenotype of pediatric OSA will have to await more extensive studies involving much larger cohorts. Accordingly, we opted not to implement additional valuable analytical methodologies to derive what we perceive as somewhat premature inferential conclusions from such methods \[[@B52],[@B53]\].

OSA is a multi-factorial and highly prevalent disorder in which both genetic and environmental factors may be involved \[[@B54],[@B55]\]. The role of specific genes that influence the development of OSA is unclear. A precise genetic foundation of OSA has been thus far difficult to identify, because it is still unknown whether some of the putative candidate genes for OSA are directly causal to the expression of the disorder or whether their role in OSA is mediated through other intermediate genes. Similarly, the phenotypic expression of OSA and its consequences is most likely determined by multiple genetic and environmental factors and their interactions. Some of the factors assumed to operate as intrinsic genetic determinants of susceptibility \[[@B56]-[@B58]\] have been shown to include inflammatory pathways, lipid membrane transport, and growth factors \[[@B58]\]. Additional external factors that have yet to be corroborated in clinical pediatric cohorts include lifestyle components, such as physical activity, and dietary habits. Previous studies have reported that several single nucleotide polymorphisms might be involved in the pathogenesis of OSA both in adult and children, such as serotonin transporter (*5-HTT*) \[[@B59]\], TNF-α \[[@B49],[@B60]\], fatty acid binding protein 4 \[[@B48],[@B61]\], macrophage migration inhibitory factor \[[@B47]\], NADPH oxidase p22 sub-unit \[[@B8],[@B50]\], and angiotensin I converting enzyme (ACE) \[[@B62],[@B63]\].

In this study, we used 536 SNPs from different genes and pathways to study the association of their allelic frequencies in children with OSA. Here, we show in a total of 209 SNPs assayed with *NOS1* gene, we identified 15 significantly SNPs those allelic frequencies were associated in children with OSA. To the best of our knowledge, no studies were conducted on genetic variance of NOS genes in children with OSA. However, several studies have been reported in human using *NOS* SNPs. For example, several polymorphisms located in *NOS1*, *NOS2*, and *NOS3* genes have been identified; some of these polymorphic sites could be responsible for variations in the genetic control of plasma *NOS* levels, which would be a useful tool for studying the relationship between *NOS* and diseases including asthma \[[@B64],[@B65]\], depressive disorder \[[@B66]\], Parkinson\'s disease \[[@B67]\], diabetic nephropathy \[[@B68]\], and stroke \[[@B69]\].

The endothelin system consists of G protein--coupled endothelin receptors (*EDNR*) that are activated by endothelin (*EDN*) signaling peptides. Specific interactions between the three different endothelin-subtypes (*EDN-1*, *-2*, *-3*) and the two human endothelin receptors (*EDNRA*, *EDNRB*) are known \[[@B70]\]. Endothelin-1 (*EDN 1*), the most potent vasoconstrictor of the human organism, uses mainly the *EDNRA* as a signal transduction pathway. Our results show different allelic frequencies of *EDN* polymorphisms between OSA subjects and controls. For example, of 155 SNPs for the three *EDN-1*,-*2* and*-3* genes and their associated *EDN* receptors (*EDNRA* and *EDNRB*), there were 4 SNPs in *EDN1*, and 1 SNP in both of *EDN2* and *EDN3*, in which allelic frequencies were significantly altered in children with OSA. We are only aware of a single published report on genetic polymorphisms in endothelin-receptor-subtype-a-gene as a susceptibility factor for adult OSA \[[@B32]\]. These investigators identified 4 candidate SNPs out of 100 in *ENDRA* in patients with OSA, but did not ascertain the significance of their findings by haplotype analysis. Endothelin-1(*EDN1*) is an intercellular signaling molecule expressed in many different organ systems and tissues. Although *EDN1* is best known as a potent vasoconstrictor, *EDN1* also plays important roles in the kidney, nervous system, and in the heart \[[@B71]\]. Furthermore, genetic polymorphisms in the *EDN1* promoter region have been linked to an increased incidence of left ventricular hypertrophy \[[@B72]\], and asthma \[[@B73]\], a known consequence of OSA in children \[[@B74]\]. The increased expression of *EDN1* among children with OSA in the present study would further suggest that genotype-phenotype interactions may indeed be present in pediatric OSA and its cardiovascular morbidities. Indeed, several lines of evidence derived from both clinical studies and animal models have shown that increases in circulating EDN1 in OSA \[[@B75]-[@B77]\].

Conclusion
==========

In conclusion, our results suggest that the *NOS1* and *EDN1* genes may confer an increased risk for the presence of OSA or downstream morbidity. The susceptibility to OSA is a multifactorial process and may result from genetic variants in many genes on different chromosomes. Also, genetic epidemiological studies of biological phenotypes involved in the same pathway can provide relevant information, and can contribute to unravel the mechanisms underlying complex diseases such as OSA. More specifically, the changes in EDN1 gene expression particularly when combined with differences in the distribution of EDN1 polymorphisms, suggest these specific SNPs influence the genetic predisposition to OSA. Thus, analysis of the currently identified EDN1 polymorphism may be useful in the assessment of risk for OSA in a high risk population, such as those children who manifest snoring or have enlarged tonsils and adenoids. Further studies should be carried out to confirm the association reported herein in expanded pediatric cohorts, and tentatively include protein and gene expression levels to enable deciphering the importance and functionality of these genetic factors.
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